Serum ASCA and Liver Disease Severity in 58 PSC-IBD Patients, 2010-2023

58 adult patients with primary sclerosing cholangitis and inflammatory bowel disease were studied retrospectively at a tertiary center. The dataset likely contains demographic, clinical, and laboratory data used to assess the association between anti-Saccharomyces cerevisiae antibody (ASCA) and liver disease severity. The study was authored by figshare admin karger and last updated in April 2026.

Use Cases

• Assessing the association between ASCA seropositivity and liver stiffness measurement (LSM) based on FibroScan results mentioned in the description
• Modeling disease severity using the Amsterdam-Oxford prognostic model (AOM) score based on clinical and laboratory data
• Comparing liver outcomes between patients with ulcerative colitis and Crohn's disease based on the cohort composition described
• Investigating the relationship between serological markers and transplant-free survival risk based on the conclusions

Strengths

• Data is derived from a specific cohort of 58 adult patients with PSC-IBD, providing a focused clinical sample.
• Includes two established severity metrics: the Amsterdam-Oxford prognostic model (AOM) and liver stiffness measurement (LSM).
• Multivariable analysis was performed, adjusting for IBD subtype and disease duration, suggesting a structured analytical approach.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small at 56.7 KB, indicating a limited scope and sample size.

Provenance

Source

figshare admin karger

Collection Method

Retrospective study on adult patients at a tertiary center; medical records were reviewed.

Time Range

2010 to 2023

Freshness

Last updated 2026-04-30 05:55:20; freshness should be verified.